<!DOCTYPE html>
<html class="theme-sleek astro-STCLZLJ5" lang="en">
  <head>
    <!-- Global Metadata -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <meta name="theme-color" media="(prefers-color-scheme: light)" content="#ffffff">
<meta name="theme-color" media="(prefers-color-scheme: dark)" content="#18181b">
<!-- 
  This is an example. 
  Use https://realfavicongenerator.net to generate the icons and manifest. 
-->
<link href="/favicon.ico" rel="shortcut icon">

    <!-- Primary Meta Tags --><title>Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.</title>
<meta name="title" content="Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.">
<meta name="description" content="Medical Cannabis Awareness New Zealand">


<!-- Open Graph / Facebook -->
<meta property="og:title" content="Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.">
<meta property="og:description" content="Medical Cannabis Awareness New Zealand">
<meta property="og:type" content="article">
<meta property="og:url" content="https://mcanz.org.nz/blog/cost-effectiveness-sativex-ms">

<meta property="article:published_time" content="2016-01-09T00:00:00.000Z">





<!-- Twitter -->
<meta property="twitter:title" content="Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.">
<meta property="twitter:description" content="Medical Cannabis Awareness New Zealand">


<meta property="twitter:card" content="summary_large_image">


<!-- {twitter.url && <meta property="twitter:url" content={twitter.url} />} -->

  <link rel="stylesheet" href="/assets/_slug_.2607fc28.css" />
<link rel="stylesheet" href="/assets/_slug_.f022e152.css" /></head>

  <body class="text-text-body bg-bg-body max-w-3xl mx-auto px-4 sm:px-8 astro-STCLZLJ5">
    <header class="astro-FAM4J5CX">
  <a class="skip-to-main astro-FAM4J5CX" href="#main"> Skip to content</a>
  <nav class="astro-FAM4J5CX">
    <section class="astro-FAM4J5CX">
      <ul class="astro-FAM4J5CX">
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/" class="astro-FAM4J5CX header-link unset animated gradient-colors astro-C675TBRQ">Home</a>
</li>
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/blog" class="astro-FAM4J5CX active header-link unset animated gradient-colors astro-C675TBRQ">Blog</a>
</li>
      </ul>
    </section>
  </nav>
</header>

    <main id="main" class="astro-STCLZLJ5">
      <section class="blog-post astro-STCLZLJ5">
        <h1 class="title astro-STCLZLJ5">Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.</h1>
        <time class="publish-date astro-STCLZLJ5">Jan 9, 2016</time>
        <article><p>Authors <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Slof%20J%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=25771713">Slof J</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Ruiz%20L%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=25771713">Ruiz L</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Vila%20C%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=25771713">Vila C</a>.</p><p><strong>Abstract;</strong></p><p>Multiple sclerosis (MS) is a chronic progressive disease that carries a high socioeconomic burden. Spasticity (rigidity and spasms) is common in MS and contributes to MS-related disability. This study aims to evaluate the cost-effectiveness of Sativex(®) (9-delta-tetrahydrocannabinol plus cannabidiol oromucosal spray) when used as add-on therapy for management of resistant MS-related spasticity in the context of the Italian healthcare system. A previously published Markov model-based analysis for the German and Spanish context was replicated, adapting it to the Italian setting. Model parameters were updated to reflect recent findings about MS-related spasticity and use of Sativex in daily clinical practice. The base case incremental cost-effectiveness ratio for Sativex use in Italy over a 5-year period was estimated to be €4968 per quality-adjusted life-year gained (year of costing: 2013). Sativex remained an efficient option in the Italian healthcare context - below the commonly accepted incremental threshold of €30,000 per quality-adjusted life-year gained - when deterministic and probabilistic sensitivity analyses were conducted. Sativex can be regarded as a cost-effective treatment option for patients with MS-related spasticity in Italy.</p><p>Full paper available for <a href="http://www.tandfonline.com/doi/abs/10.1586/14737167.2015.1025759?journalCode=ierp20">purchase here.</a></p></article>
      </section>
    </main>
    <footer class="astro-5AYKG27L">
  <div class="astro-5AYKG27L">

  </div>
</footer>


  
</body>


</html>